Geron Presents Data at ISSCR Showing That Its Embryonic Stem Cell Therapeutic for Heart Failure Evades Direct Attack by the Human Immune System

<p>MENLO PARK, Calif.–(BUSINESS WIRE)–Geron Corporation (Nasdaq:GERN) today announced the presentation of research studies indicating that GRNCM1, the company&rsquo;s human embryonic stem cell (hESC)-based therapeutic for the treatment of heart failure, evades direct attack by…</p>